Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells

Although MEK blockade has been highlighted as a promising antitumor drug, it has poor clinical efficacy in KRAS mutant colorectal cancer (CRC). Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a parallel signaling pathway, thereby d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheon, Seul‐Ki, Kim, Hwang‐Phill, Park, Ye‐Lim, Jang, Jee‐Eun, Lim, Yoojoo, Song, Sang‐Hyun, Han, Sae‐Won, Kim, Tae‐You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068346/
https://www.ncbi.nlm.nih.gov/pubmed/29896883
http://dx.doi.org/10.1002/1878-0261.12345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068346/
https://www.ncbi.nlm.nih.gov/pubmed/29896883
http://dx.doi.org/10.1002/1878-0261.12345

Ejemplares similares